Defining the functional impact of T1D genes in mouse and man: a unified strategy
Defining the functional impact of T1D genes in mouse and man: a unified strategy
批准号:
8436004
负责人:
Jane Hoyt Buckner
金额:
$425.86万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-15 至 2017-03-14
关键词:
AddressAgeAnimal ModelAntigensArtsBlood specimenCellsCodeCollaborationsDevelopmentDiagnosticDiseaseExperimental DesignsFamilyFutureGene TargetingGenesGeneticGenetic VariationGenomicsGenotypeGrantHematopoieticHeterogeneityHumanHuman GeneticsImmuneImmune responseImmunologicsIndividualInsulinInsulin-Dependent Diabetes MellitusKnock-in MouseKnowledgeLeadLifeLigandsLinkLymphoidModelingMusMutationNaturePTPN22 genePathogenesisPatternPhenotypePlayPopulationResearch PersonnelRiskRoleSamplingSignal TransductionSpeedStagingSystemTYK2TherapeuticTranslatingTranslationsUmbilical Cord BloodUncertaintyVariantWorkdisorder riskexperiencegenetic analysisgenetic variantgenome wide association studyhigh riskhomologous recombinationhuman datahuman subjectimmune activationimmune functionin vivoinsightmanmouse genomenovelnovel strategiespathogenpathogen exposureperipheral bloodresponseskillstranslational study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): It is clear that genes play a significant role in the development of T1D. Progress has been made but several hurdles have impeded progress in defining the functional consequences of the genes associated with T1D risk. These include the modest risk associated with individual genomic regions and uncertainty as to which of the SNPs in these regions are causative limiting mechanistic studies relating genotype to phenotype. The multiplicity of genes and the heterogeneity among individuals poses further complexity to the study of the functional consequences of variation in genes in the human subjects, while murine models may not reflect the impact of a gene on the human immune response. To overcome each of these hurdles we propose a novel strategy to define the functional significance of novel genetic variants in T1D by integrating three different approaches: Aim 1: We will utilize a novel genetic approach to identify causative genetic loci in T1D thus identifying variants that can be studied in a targeted manner in mouse and man. Aim 2: We will model causative variants in mice allowing us to study the impact of the genetic variants on immune development, in multiple cell population and in response to in vivo antigen exposure. Aim 3: We will define the functional phenotypes related to these causative genetic variants in humans with and without T1D. The studies will be in part driven by findings in murine models while they will also determine the relevance of findings from these models to human subjects and T1D. Each aim will be directed by an expert in their field, who has a strong track record for successful collaboration in genotype- phenotype studies of T1D. This approach is unique in that although each Aim will be distinct in its approach findings from each Aim of this project will influence the direction and experimental design of the other aims. The initial studies in Aim 2 and 3 will focus on coding variants already identified through the work of genetic studies; PTPN22, SH2B3, TYK2 and IFIH1. Future studies using this integrated strategy will incorporate genetic variants identified b studies performed in Aim 1- defining addition causative genetic variants associated with T1D. The integration of these approaches will overcome hurdles that now limit progress in T1D genetics, will enhance our understanding of several T1D associated genetic variants, and will also develop a platform for studies of additional genes that will promote a better mechanistic understanding of T1D disease pathogenesis.
PUBLIC HEALTH RELEVANCE: T1D is a disease leading to a lifelong requirement for treatment with insulin, and the potential for devastating complications later in life. Genes are known to contribute to the risk of disease, how these genes lead to disease requires an understanding of their functional impact. In this grant we propose a novel strategy that will speed our understanding of how genes known to be associated with T1D lead to this disease; such knowledge will assist future research, but also assist in developing diagnostic and therapeutics for individuals at risk of or with T1D.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease
-
批准号:10871040
-
项目类别:
-
资助金额:$49.27万
-
财政年份:2023
-
负责人:Jane Hoyt Buckner
-
依托单位:
T cells promoting transitions toward autoimmunity
-
批准号:10658696
-
项目类别:
-
资助金额:$131.63万
-
财政年份:2023
-
负责人:Jane Hoyt Buckner
-
依托单位:
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease (Admin Supp)
-
批准号:10933073
-
项目类别:
-
资助金额:$26.02万
-
财政年份:2023
-
负责人:Jane Hoyt Buckner
-
依托单位:
Harnessing engineered T regulatory cells to promote beta cell health in T1D
-
批准号:10436687
-
项目类别:
-
资助金额:$99.34万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Clinical Core
-
批准号:10420945
-
项目类别:
-
资助金额:$32.63万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Harnessing engineered T regulatory cells to promote beta cell health in T1D
-
批准号:10605317
-
项目类别:
-
资助金额:$97.57万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Clinical Core
-
批准号:10598119
-
项目类别:
-
资助金额:$103.61万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity
-
批准号:10204509
-
项目类别:
-
资助金额:$210.02万
-
财政年份:2020
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:10248349
-
项目类别:
-
资助金额:$42.34万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:10480055
-
项目类别:
-
资助金额:$90.13万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Anti-tumor and autoimmunity signatures in Down syndrome
-
批准号:10848979
-
项目类别:
-
资助金额:$64.88万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:9812541
-
项目类别:
-
资助金额:$87.48万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:10682446
-
项目类别:
-
资助金额:$84.56万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the functional impact of T1D genes in mouse and man: a unified strategy
-
批准号:8686992
-
项目类别:
-
资助金额:$14.34万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the role of altered cytokine signaling pathways on autoimmunity
-
批准号:8680005
-
项目类别:
-
资助金额:$245.08万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the role of altered cytokine signaling pathways on autoimmunity
-
批准号:8492031
-
项目类别:
-
资助金额:$230.37万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the role of altered cytokine signaling pathways on autoimmunity
-
批准号:8373725
-
项目类别:
-
资助金额:$245.08万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Impact of the autoimmunity associated PTPN22 1858T
-
批准号:8705359
-
项目类别:
-
资助金额:$44.58万
-
财政年份:2011
-
负责人:Jane Hoyt Buckner
-
依托单位:
Impact of the autoimmunity associated PTPN22 1858T
-
批准号:8042482
-
项目类别:
-
资助金额:$42.91万
-
财政年份:2011
-
负责人:Jane Hoyt Buckner
-
依托单位:
Impact of the autoimmunity associated PTPN22 1858T
-
批准号:8517562
-
项目类别:
-
资助金额:$41.91万
-
财政年份:2011
-
负责人:Jane Hoyt Buckner
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: